| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Institute of Applied Radiobiology and Immunology, ITRI-TNO, 2280 HV Rijswijk, the Netherlands
Rat R2k rhabdomyosarcoma cells were transfected with the human H-ras oncogene, which resulted in increased resistance to cell kill in vitro by a single dose of 137Cs 
-rays. A subline carrying one oncogene showed an increase in the quasi-threshold dose (Dq) from 0.88 to 1.48 Gy. Another subline containing six oncogenes not only had an increased Dq of 1.59 Gy but also showed an increase in the dose reducing cell survival to a fraction of e-1 = 0.37 (Do) from 1.25 to 1.76 Gy. Analysis of the cell survival data according to the linear-quadratic formalism indicated that a decrease in the value of the coefficient of the linear component 
is associated with a H-ras-mediated increase in radioresistance. In fractionated irradiation experiments it was observed that with a dose of 1 Gy/fraction a 1.8 times higher dose for an isoeffect of 10% cell survival (D10) was needed for a subline with one H-ras oncogene, while with fraction doses of 2 or 4 Gy only a 1.2 times higher D10 was found. This indicates a more efficient repair of radiation-induced damage in the transfected subline. Tumors arising in the rat gastrocnemius muscle inoculated with cultured cells were irradiated with different doses of 300-kV X-rays. A single dose of 45 Gy was found to result in a 6% cure rate for the subline containing one H-ras oncogene and a 32% for the parental line. When a priming dose of 45 Gy was followed by fractionated irradiation with 1 Gy/fraction, an extra dose of 51 Gy would be needed to obtain a 75% cure rate for the transfected subline. An extra dose of only 10 Gy would be needed for the parental line. The percentage cure per unit of dose for the parental line irradiated with 1 Gy/fraction was estimated to be 4.3%·Gy-1, whereas for the transfected tumor line it was 1.4%·Gy-1. This means that a 3.0 times higher cumulated absorbed dose would be needed for enhancing the cure rate from 32% to 75% in the subline with H-ras than for the parental line. With 2 Gy/fraction the difference in extra doses required for obtaining isolevels of cure rates was found to be small, a factor of 1.4. The results indicate that in the course of fractionated irradiation with 1 Gy/fraction, in vivo repair is much more efficient in the transfected subline.
1 To whom requests for reprints should be addressed, at Institute of Applied Radiobiology and Immunology, ITRI-TNO, P. O. Box 5815, 2280 HV Rijswijk, The Netherlands.
Received 8/21/91. Accepted 3/25/92.
This article has been cited by other articles:
|
|
 |
|
  J. B. Weidhaas, D. M. Eisenmann, J. M. Holub, and S. V. Nallur A Conserved RAS/Mitogen-Activated Protein Kinase Pathway Regulates DNA Damage-Induced Cell Death Postirradiation in Radelegans Cancer Res., November 1, 2006; 66(21): 10434 - 10438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-Y. Chang, C.-K. Youn, H.-B. Kim, M.-H. Kim, H.-J. Cho, Y. Yoon, Y.-S. Lee, M.-H. Chung, and H. J. You Oncogenic H-Ras Up-regulates Expression of Ku80 to Protect Cells from {gamma}-Ray Irradiation in NIH3T3 Cells Cancer Res., August 1, 2005; 65(15): 6811 - 6819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. KIM, J. SEONG, and S. H. KIM Enhancement of Tumor Response by Farnesyltransferase Inhibitor in C3H/HeJ Hepatocarcinoma Ann. N.Y. Acad. Sci., December 1, 2004; 1030(1): 95 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-K. Youn, M.-H. Kim, H.-J. Cho, H.-B. Kim, I.-Y. Chang, M.-H. Chung, and H. J. You Oncogenic H-Ras Up-Regulates Expression of ERCC1 to Protect Cells from Platinum-Based Anticancer Agents Cancer Res., July 15, 2004; 64(14): 4849 - 4857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Grana, C. I. Sartor, and A. D. Cox Epidermal Growth Factor Receptor Autocrine Signaling in RIE-1 Cells Transformed by the Ras Oncogene Enhances Radiation Resistance Cancer Res., November 15, 2003; 63(22): 7807 - 7814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Brunner, S. M. Hahn, A. K. Gupta, R. J. Muschel, W. G. McKenna, and E. J. Bernhard Farnesyltransferase Inhibitors: An Overview of the Results of Preclinical and Clinical Investigations Cancer Res., September 15, 2003; 63(18): 5656 - 5668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Grana, E. V. Rusyn, H. Zhou, C. I. Sartor, and A. D. Cox Ras Mediates Radioresistance through Both Phosphatidylinositol 3-Kinase-dependent and Raf-dependent but Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase-independent Signaling Pathways Cancer Res., July 15, 2002; 62(14): 4142 - 4150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Cho, H. G. Jeong, J.-S. Lee, E.-R. Woo, J.-W. Hyun, M.-H. Chung, and H. J. You Oncogenic H-Ras Enhances DNA Repair through the Ras/Phosphatidylinositol 3-Kinase/Rac1 Pathway in NIH3T3 Cells. EVIDENCE FOR ASSOCIATION WITH REACTIVE OXYGEN SPECIES J. Biol. Chem., May 24, 2002; 277(22): 19358 - 19366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Bernhard, E. J. Stanbridge, S. Gupta, A. K. Gupta, D. Soto, V. J. Bakanauskas, G. J. Cerniglia, R. J. Muschel, and W. G. McKenna Direct Evidence for the Contribution of Activated N-ras and K-ras Oncogenes to Increased Intrinsic Radiation Resistance in Human Tumor Cell Lines Cancer Res., December 1, 2000; 60(23): 6597 - 6600. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
